Members of the transglutaminase family catalyze the formation of isopeptide bonds between a polypeptide-bound glutamine and a low molecular weight amine (e.g., spermidine) or the E-amino group of a polypeptide-bound lysine. Transglutaminase 2 (TG2), a prominent member of this family, is unique because in addition to being a transamidating enzyme, it exhibits numerous other activities. As a result, TG2 plays a role in many physiological processes, and its function is highly cell type specific and relies upon a number of factors, including conformation, cellular compartment location, and local concentrations of Ca 21 and guanine nucleotides. TG2 is the most abundant transglutaminase in the central nervous system (CNS) and plays a pivotal role in the CNS injury response. How TG2 affects the cell in response to an insult is strikingly different in astrocytes and neurons. In neurons, TG2 supports survival.
| I N TR ODU C TI ON
Transglutaminase 2 (TG2), also known as tissue transglutaminase, is a unique member of the transglutaminase family as it is ubiquitously expressed, catalyzes a number of different reactions and is involved in mediating numerous molecular processes. In addition to its transamidating activity, TG2 has been shown to function as a GTPase, a protein disulphide isomerase and a molecular scaffold (Gundemir, Colak, Tucholski, & Johnson, 2012) . The function that TG2 takes on relies upon a number of variables including cell type, intracellular localization, and extracellular environment. In addition, the multifunctionality of TG2 is mediated by its different domains and conformations. TG2 contains four domains; an N-terminal b sandwich domain, a catalytic domain, and two C-terminal b barrel domains (Lorand & 
Significance
Transglutaminase 2 (TG2) is a protein that plays key roles in cell death and survival processes. TG2 is expressed in both neurons and astrocytes in the central nervous systems (CNS); however, how TG2 affects survival following injury is extraordinarily different in these two cell types. In neurons, TG2 supports survival subsequent to ischemic injury and TG2 knockdown results in loss of neuronal viability. The opposite is true in astrocytes; deletion of TG2 increases survival after ischemia.
Here, we discuss the differing roles of TG2 in neurons and astrocytes, as well as underlying molecular mechanisms that may contribute to these differences. Graham, 2003) . The transamidating activity is mediated by the catalytic domain and Ca 21 binding is required for activation which facilitates a more open conformation of the protein, while guanine diphosphate and triphosphate (GDP and GTP, respectively) binding promote a more closed conformation and inhibition of transamidating activity (Achyuthan & Greenberg, 1987; Liu, Cerione, & Clardy, 2002; Pinkas, Strop, Brunger, & Khosla, 2007) . The structural differences between the closed and open conformations are quite remarkable. When the predicted structure of TG2 in its fully extended conformation is aligned with TG2 in its closed, GTP/GDP bound conformation the C-terminal residues are displaced by up to 120 Å ( Figure 1 ). In response to this large conformational shift in tertiary structure, there is also a change in secondary structure which results in backbone rearrangements that further extend the catalytic active site (Pinkas et al., 2007 ion. All five of these sites play a role in the catalytic activity of TG2 (Kiraly et al., 2009) . Binding of Ca 21 to these sites forces TG2 into an open conformation that allows substrates access to the catalytic triad (Cys277, His335, and Asp358), which are positioned to allow the flow of electrons required for the transamidation reaction to occur (Murthy et al., 2002; Pedersen et al., 1994) . Trp241 residue stabilizes the intermediate state of the transamidating reaction, and mutating it results in a complete loss of function (Murthy et al., 2002) . TG2 also has a GTPase function, and GTP/GDP binding inhibits the transamidating function of the catalytic core. The binding of GTP masks Arg580, a destabilizing switch residue in the first b-barrel required for GTP binding, which allows the protein to take on its closed, inactive conformation (Begg et al., 2006) . Thus, the transamidating activity of TG2 is activated by Ca
21
, and inhibited by GDP and GTP. Under normal physiological conditions, it would be expected that the closed inactive form of TG2 would dominate in the cytosol, as intracellular concentrations
of GTP surpass what is required for binding, and Ca 21 concentrations are insufficient for binding to occur (Eckert et al., 2014; Gundemir et al., 2012 being active as a transamidating enzyme. This, however, is not the case. TG2 is predominantly inactive in the extracellular space, until it is activated by a stimulus such as inflammatory mediators. This is due to a triad of cysteine residues (Cys230, Cys370, and Cys371) that act as redox sensor for TG2 (Stamnaes, Pinkas, Fleckenstein, Khosla, & Sollid, 2010 Indeed, the functioning of numerous transcription factors have been shown to be regulated by TG2 (Eckert et al., 2014; Gundemir et al., 2012 the activity of CREB in these cells (Obara et al., 2013) . Similar findings were reported in an earlier study using human neuroblastoma SH-SY5Y cells. In these cells, overexpression of wild-type TG2, but not a C277S mutant that lacks transamidating activity and the ability to efficiently bind GTP (Begg et al., 2006; Gundemir & Johnson, 2009) A substantial number of studies have shown that TG2 regulates the activity of the transcription factor nuclear factor kappa B (NF-jB), although how TG2 affects NF-jB signaling varies significantly depending on the cell type. In the cancer cell models that have been examined, TG2 has been shown to activate NF-jB (Agnihotri, Kumar, & Mehta, 2013; Eckert et al., 2014; Mann et al., 2006) . Overexpression of TG2 in HEK cells also increased NF-jB activity (Jang et al., 2010) , and in immortalized activated murine microglia (BV-2 cells) TG2 activates NFjB in response to lipopolysaccharide treatment, and this resulted in increased expression of inducible nitric oxide synthase (Lee et al., 2004) . Interestingly, there is data suggesting that TG2 potentiates renal ischemic injury by increasing NF-jB activation ). It appears that TG2 increases NF-jB activity by inducing the polymerization of the inhibitory IjBa which would require TG2 to be active as a transamidating enzyme (Lee et al., 2004) and/or by binding to IjBa and facilitating its degradation by a nonproteasomal dependent pathway in a transamidation independent manner (Kumar & Mehta, 2012) . As an illustration of the latter, overexpression of either wild-type TG2 or the C277S mutant in breast cancer cells activated NF-jB (Kumar & Mehta, 2012) . Overall, these data indicate that TG2 upregulates NF-jB activity in cancer cells, immortalized cell lines, and primary non-neural cells. In contrast to these findings, depletion or deletion of TG2 in primary astrocytes results in a significant and robust increase in NF-jB activity.
Intriguingly, treatment of wild-type astrocytes with the irreversible TG2 inhibitor VA4, which forces and maintains TG2 in an open conformation, resulted in a significant decrease in NF-jB activity. These findings suggest that TG2 may be acting as an adaptor to inhibit NF-jB activation, and this function is optimal when TG2 is in the open conformation (Feola, Barton, Akbar, Keillor, & Johnson, 2017) . Similar to what was observed in astrocytes; knockdown of TG2 in primary neurons significantly increases NF-jB activity (Figure 3 ), although the mechanisms involved have not been defined. These findings strongly indicate that the molecular roles that TG2 plays in the nervous system are likely fundamentally different from how it functions in non-neural systems.
Hypoxia inducible factor (HIF) signaling is likewise regulated by TG2. In breast cancer cells, overexpression of TG2 results in a constitutive upregulation of HIF1a, increased hypoxic response element (HRE) activation, and thus increased expression of HIF responsive genes (Kumar, Donti, Agnihotri, & Mehta, 2014) . This increase in HIF signaling is proposed to be due to TG2 dependent activation of NF-jB signaling which increases the expression of HIF1a and a gene expression profile that supports the Warburg effect (Kumar et al., 2014) . In contrast to what was observed in breast cancer cells, in human neuroblastoma FIGURE 2 Depletion of transglutaminase 2 (TG2) in neurons attenuates Cre luciferase reporter activity. Primary rat cortical neurons were transduced with TG2 shRNA as indicated. Five days after transduction all neurons were transfected with a Cre luciferase reporter and a promoterless null Renilla construct. Two days later, the neurons were treated with 3-isobutyl-1-methylxanthine or vehicle overnight followed by measurement of luciferase and Renilla activity. The luciferase measurements were normalized to its Renilla measurement. Results are shown as fold increase relative to vehicle-treated measurements and expressed as mean 6 SEM. *p < .05, n 5 3 (Y. Nuzbrokh and S. Gundemir)
SH-SY5Y cells and primary neurons TG2 significantly attenuates hypoxia-induced HIF activation, and this inhibition is not dependent on its transamidating activity or GTP binding (Filiano, Bailey, Tucholski, Gundemir, & Johnson, 2008; Gundemir, Colak, Feola, Blouin, & Johnson, 2013) . Further, it was demonstrated that in neuroblastoma cells and neurons TG2 binds to HIF1b; however, this interaction could be separated from its ability to suppress HIF signaling. Nonetheless, nuclear localization of TG2 was required for the suppressive effect on HIF signaling and it was recruited to the HRE site in the enolase promoter. Intriguingly, in this same study overexpression of TG2 with a nuclear export signal to reduce nuclear levels, increased hypoxicinduced HRE activity in MCF-7 cells, while expression of wild type or nuclear localization sequence tagged TG2 did not. This finding may in part explain the different findings in cancer cells and neurons (Gundemir et al., 2013) .
Depending on the cell type TG2 can localize to the extracellular matrix (ECM), cell surface, cytoplasm, mitochondria, and in the nucleus (Gundemir et al., 2012) . Under normal conditions, between 5 and 10% of endogenous TG2 localizes to the nucleus (Lesort, Attanavanich, Zhang, & Johnson, 1998; Park, Choi, & Ha, 2010) , and in the nucleus of human neuroblastoma cells TG2 is found primarily in the chromatin fraction (Lesort et al., 1998) . The subcellular localization of TG2, as well as its conformational and activity state, likely plays a major role in determining how it affects cell signaling events and thus survival. In tumor cells
and cancer stem cells, TG2 expression levels are increased and this promotes cell survival (Eckert et al., 2015) . Further, the ability of TG2
to support the survival of cancer seems to require that it be in a GTP bound closed conformation (Eckert et al., 2015) . In neurons, TG2 has differential effects on survival, which likely depends on its activation state. In a mouse model where human TG2 was overexpressed in neurons, increased neuronal cell death was observed subsequent to kainic acid induced seizures. In this model, TG2 takes on a more open conformation with increased transamidating activity due to significantly elevated intraneuronal Ca 21 levels (Tucholski, Roth, & Johnson, 2006) .
However, in the same mouse model of human TG2 overexpression in neurons, there was a significant decrease in infarct volume following permanent middle cerebral ligation (MCAL) (Filiano, Tucholski, Dolan, Colak, & Johnson, 2010) . In primary neurons, overexpression of wildtype TG2 or the C277S mutant (which is transamidating inactive and deficient in GDP/GTP binding [Begg et al., 2006; Gundemir & Johnson, 2009] ), protected against oxygen and glucose deprivation (OGD)-induced cell death (Filiano et al., 2008) . Further, in SH-SY5Y cells, knocking down TG2 resulted in a significant increase in OGD-induced cell death (Gundemir et al., 2013) . When TG2-R580A, which does not bind guanine nucleotides and thus exhibits a more open conformation and a high basal transamidating activity (TG2-R580K exhibits the same characteristics [Begg et al., 2006] ), was expressed in immortalized striatal cells, increased cell death was observed following OGD compared to cells expressing vector only. However, if TG2-R580A was targeted to the nucleus the detrimental effects were significantly attenuated (Colak, Keillor, & Johnson, 2011 ). These findings demonstrate that in neurons, and neuronally derived cells, the localization and activation state of TG2 plays a critically important role in determining cell survival outcomes.
FIGURE 4 Deletion of transglutaminase 2 (TG2) in astrocytes significant increases the levels of lactate, malate, and a-ketoglutarate after ischemic stress. Primary astrocytes from wildtype (closed symbols) and TG2-/-(open symbols) mice were exposed to 90 min of oxygen and glucose deprivation (0.1% O 2 ) followed by 24 hr of reperfusion. Cells were snap frozen and metabolites were extracted with 80% methanol. Extracted metabolites were analyzed using reverse phase chromatography with an ion-pairing reagent in a Shimadzu HPLC coupled to a Thermo Quantum triple-quadrupole mass spectrometer (Nadtochiy et al., 2015) . Data are expressed relative to wild-type astrocytes. Results are shown as mean 6 SEM. *p < .05, n 5 8 (A. Monteagudo) FIG URE 3 The depletion of transglutaminase 2 (TG2) increases nuclear factor kappa B (NF-jB) luciferase reporter activity. Primary rat cortical neurons were transduced with TG2 shRNA or scrambled control. Five days after transduction, the neurons were transfected with an NF-jB luciferase reporter and a promoterless null Renilla construct. Two days later, the neurons were exposed to hypoxia (0.1% O 2 ) or normoxia for 14 hr, followed by measurement of luciferase and Renilla expression. The luciferase measurements were normalized to its Renilla measurement. Final results were normalized to control measurements. Results are shown as mean 6 SEM. **p < .01. ****p < .0001. n 5 5 biological replicates with 5-6 separate wells for each condition
In contrast to neurons, the role that TG2 plays in astrocytes to regulate cell death/survival is very different. Given the initial finding that overexpression of human TG2 in neurons significantly decreased infarct volume following MCAL (Filiano et al., 2010) , it was reasoned that complete deletion of TG2 should worsen outcomes. In fact, just the opposite was true. Infarct volumes were significantly smaller in complete TG2 knockout (TG2-/-) mice following MCAL . Upon further investigation, it was found that, as expected, TG2-/-neurons were more susceptible to OGD-induced cell death than wild-type neurons, but the opposite was true for the TG2-/-astrocytes, as they were more resistant to OGD-induced cell death than wild-type astrocytes. When astrocytes were cocultured with neurons it was found that TG2-/-astrocytes were able to protect wildtype or TG2-/-neurons from OGD-induced cell death to a significantly greater extent than wild-type astrocytes . In further studies, it was also found that knocking down TG2 in astrocytes with TG2 shRNA also significantly increased their viability following OGD and their ability to protect neurons.
While further investigation is needed, one possible explanation for this phenomenon could be that TG2 knockout in astrocytes could result in changes in the metabolic pathways that produce products that are released to protect neurons. In support of this hypothesis, it was found that TG2-/-astrocytes produce higher levels of malate, lactate, and a-ketoglutarate than wild-type astrocytes subsequent to OGD ( Figure   4 ). It is noteworthy that astrocytes normally release lactate as a result of anaerobic metabolism, and this can be taken up by neurons through channels called monocarboxylate transporters (Falkowska et al., 2015 Knockdown or knockout of TG2 in astrocytes significantly increased NF-jB activity, while treatment with VA4 resulted in a significant inhibition .
While the effect of TG2 on NF-jB signaling can be separated from its effect on astrocyte survival, it may play a role in the ability of astrocytes to promote survival of neurons in the context of excitotoxicity. In excitotoxicity, there is excessive excitation of glutamatergic neurons leading to an inappropriate release of glutamate into the synapse. A primary defense against excitotoxicity is the uptake of glutamate by astrocytes, and glutamate transporter 1 (GLT-1) plays a major role in mediating this process. One study found that GLT-1 expression in astrocytes that are cocultured with neurons is dependent upon NF-jB signaling in the astrocytes (Ghosh, Yang, Rothstein, & Robinson, 2011) .
Additionally, it has been demonstrated that treatment of primary rat astrocytes with glutamate increased TG2 expression (Campisi et al., 2003) , concurrent with increased nuclear localization of NF-jB subunits, as well as increased binding of these subunits to the promoter of TG2 (Caccamo et al., 2005) . Taken together, it can be suggested that excessive glutamate may result in an increase of NF-jB nuclear localization and activity, which in turn increases the expression of GLT-1 in astrocytes. This would allow astrocytes to remove the excess glutamate from the synapse and protect neurons from excitotoxicity. However, as TG2 inhibits the activity of NF-jB in astrocytes this could reduce the ability of astrocytes to protect neurons from excitotoxicity ( Figure 5 ).
Clearly further studies are needed to understand why TG2 differentially affects survival in neurons and astrocytes, although one clue may be that in response to stress the localization patterns of TG2 differ significantly. In hypoxic conditions, the levels of TG2 in the nucleus of neurons increase significantly, while in astrocytes there is a significant decrease in nuclear TG2 (Yunes-Medina, .
These data provide a conceptual framework in which nuclear TG2 is protective while cytosolic TG2 is detrimental to survival, due to increased transamidating activity resulting from the open conformation assumed by TG2. This observation may provide a clue as to why TG2
FIG URE 5 Hypothetical model illustrating how transglutaminase 2 (TG2) mediated suppression of nuclear factor kappa B (NF-jB) signaling in astrocytes could compromise the ability of astrocytes to protect against neurons against excitotoxicity. In pathological conditions where there is excessive excitation of glutamatergic neurons and release of glutamate, the primary protective response is uptake of glutamate by astrocytes and glutamate transporter 1 (GLT-1) plays a major role in this process. GLT-1 expression in astrocytes is mediated by NF-jB signaling (Ghosh et al., 2011) . Glutamate treatment of astrocytes results in increased nuclear localization of NF-jB subunits, as well as increased binding of these subunits to the promoter of TG2 (Caccamo et al., 2005) which can increase TG2 expression (Mirza et al., 1997) . Given that in astrocytes TG2 represses NF-jB activity , this could lead to decreased GLT-1 expression which would result in decreased glutamate uptake. [Color figure can be viewed at wileyonlinelibrary.com] differentially impacts stress-induced cell death in neurons and astrocytes.
| THE ROLE OF TG2 IN CELLULAR S T RU CT U RA L DY NA M I CS
In many different cell types, TG2 increases adhesion, migration, and cellular spreading (Eckert et al., 2014) , including astrocytes and neurons. There is good evidence that TG2 facilitates the interaction of astrocytes with the ECM and supports astrocyte migration, and in nervous system injury models could contribute to the formation of glial scars van Strien, Drukarch, et al., 2011) .
Treatment of astrocytes with pro-inflammatory cytokines increased expression, externalization, and activity of TG2 which plays a pivotal role in stimulating the formation of focal adhesions and mediating astrocyte migration . Deletion of TG2 or inhibition with irreversible inhibitor VA4 significantly reduced the motility of cultured astrocytes. Further, the migration defect in TG2-/-astrocytes could only be rescued with wild-type TG2; neither the R580A mutant (that does not bind GTP/GDP and exhibits increased transamidating activity) nor the W241A mutant (which is transamidating inactive) was able to restore motility (Monteagudo, Ji, Akbar, Keillor, & Johnson, 2017) . These findings are in agreement with an earlier study that showed the transglutaminase inhibitor KCC009 also inhibited astrocyte migration . These data suggest that both transamidation and guanine nucleotide binding are essential for TG2 to facilitate astrocyte migration. It is also interesting to note that migration could be rescued in TG2-/-astrocyte with the addition of TGFb1, an inflammatory cytokine that is also known to induce reactive astrogliosis (Monteagudo et al., 2017) . This would suggest that TG2 activates migration in a pathway that is independent of the TGFb receptor, perhaps by inducing migration through mitogen activated protein (MAP) kinase-mediated reorganization of actin (Zarubin & Han, 2005) . Additionally, TG2 has been shown to interact with fibronectin in the ECM , resulting in the activation of b1 integrins, a family of proteins involved in the regulation of the cellular adherence and cytoskeletal rearrangement required for migration (Telci et al., 2008) . TG2 similarly plays a role in facilitating remodeling in neuronal cells. Overexpression of wild-type TG2, but not the C277S mutant, resulted in spontaneous neurite outgrowth in SH-SY5Y cells in low serum (Tucholski, Lesort, & Johnson, 2001) , and differentiation of wild-type SH-SY5Y cells in the presence of a TG2 inhibitor resulted in significant inhibition of neurite outgrowth (Song et al., 2013) . Further, in primary neurons, knocking down TG2 results in a pronounced decrease in neurite length (Yunes-Medina, Paciorkowski, Nuzbrokh, & Johnson, 2018) . Intriguingly, TG2 also appears to play a significant role in stabilization of axonal microtubules by catalyzing the incorporation of polyamines into tubulin. Indeed, the levels of coldstable microtubules were significantly reduced in young TG2-/-mouse brain and spinal cord relative to the levels in age-matched wild-type mice (Song et al., 2013) . These data suggest that in both astrocytes and neurons the roles that TG2 plays in mediating cellular structural dynamics require a catalytically active protein and that similar mechanisms may be involved.
| TG2 SU P P OR TS N EU R ON AL SU R VI V A L
The fact that nuclear localization of TG2 is key to its ability to play a protective role, and that it primarily localizes to the chromatin fraction, suggest that transcriptional regulation by TG2 is likely of fundamental
importance. An unbiased approach using RNA-sequencing (RNA-seq) on neurons transduced with TG2 shRNA or a scrambled (scr) version yielded interesting results . Intriguingly, simply depleting TG2 resulted in a loss of neuronal viability. To ensure that any changes observed in gene expression were not simply due to the loss of viability, RNA-seq was carried out on samples from transduced neurons collected at a time point prior to any loss of viability. Differentially expressed gene analysis revealed that the expression of 86 genes was changed due to knocking down TG2, with the majority (59) of these being upregulated. In addition, enriched pathway analysis revealed that the genes differentially expressed in neurons after TG2
knockdown were predominantly involved in cell signaling, ECM (Ji, Paciorkowski, Tang, & Johnson, 2018) . Interestingly, increases in cathepsin s have been associated with Alzheimer's disease relevant neurodegenerative processes Munger et al., 1995; Nubling et al., 2017) and inhibition of cathepsin k facilitates neurite outgrowth (Obermajer, Doljak, Jamnik, Fonovic, & Kos, 2009 ). These and other findings suggest that in neurons, TG2 plays a direct role in the mediating gene transcription by regulating the repression of genes involved in cytoskeletal rearrangement and cell-matrix interactions, and thus neurite extension and remodeling. The expression of genes in a healthy cell is dependent on a balance between activation and repression. It can be speculated that knockdown of TG2 in neurons disrupts this balance and, given the genes that are affected, the result is unhealthy neurites which in turn negatively impact neuron survival. In astrocytes, knockdown of TG2 does not result in loss of viability ; however, their ability to extend their filopodia and migrate is significantly reduced (Monteagudo et al., 2017) . Although there are similarities between the processes involved in neurite and filopodia dynamics, it is likely that TG2 differentially affects these cellular events in neurons and astrocytes. For example, TG2 is externalized by astrocytes, but not neurons (van Strien, Baron, et al., 2011; Yunes-Medina et al., 2017) , and the interaction of TG2 with the ECM plays an important role in modifying the ability of astrocytes to extend their filopodia and migrate (van Strien, Baron, et al., 2011; .
| C O NC LU S I ON S A ND F U TU R E D I RE CT ION S
In summary, TG2 plays key, but often quite different, roles in neurons and astrocytes (see Table 1 ). Indeed, knocking down TG2 in neurons compromises viability, while in astrocytes knocking down TG2 has no significant effect on viability in control conditions and significantly increases survival after an ischemic insult. Interestingly, in vivo the negative effects of TG2 activity in astrocytes seem dominant over the positive effects in neurons. This is demonstrated in the cases of ischemic stroke, where global TG2 deletion results in decreased stroke volumes following an MCAL model despite there being increased OGD-induced cell death in TG2-/-neurons when they are in culture. Further, in a coculture paradigm TG2-/-astrocytes increased neuronal survival compared to wild-type astrocytes after OGD, regardless of whether or not the neurons contained TG2 themselves .
This would suggest that the potentially detrimental role of TG2 in astrocytes plays a greater role in the response to CNS ischemic insult than the protective role in neurons, basically in the intact CNS "less is better" in the case of TG2 following an injury. This also might hold true for other conditions such as neurodegenerative diseases. For example, when TG2-/-mice were crossed with mice expressing mutant huntingtin protein neuronal cell death was decreased (Mastroberardino et al., 2002) . This was originally attributed to TG2 playing a detrimental role in neurons, however, more recent data suggests it could be due an enhanced beneficial effect of the TG2 deficient astrocytes.
Overall, it is clear that the functions of TG2 are cell type and situation specific, and generalizing the function of TG2 based on findings in a given cell type and circumstance often cannot be done. Of critical importance going forward is to understand what governs the differential localization of TG2 in neurons and astrocytes, as well as the cell type specific interactors. Additionally, it is crucial to determine the role of conformation and activity state in astrocytes and neurons in control and stress conditions, and how this impacts outcomes. TG2 is truly a multifunctional protein that modulates numerous cellular processes.
Delineating the underlying mechanisms that are responsible for the seeming paradoxical roles of TG2 in astrocytes and neurons will provide a better understanding of the response of the nervous system to insults and may provide new targets for improved treatments for ischemic stroke and other related injuries.
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